Provepharm life Solutions

What Provepharm life Solutions does

Provepharm Life Solutions is a privately-held French specialty pharmaceutical company founded in 1998 in Marseille, focused on the development, manufacture, and distribution of high-purity medical dyes for surgical visualization, endoscopic procedures, and diagnostic applications. Its core portfolio centers on methylene blue-based products (Proveblue, PROVEDYE, ProvayBlue) and indigo carmine-based products (Provingo, PROVENDO, Bludigo, Blumyne), sold as both pharmaceutical medicines and medical devices in ampoules, vials, and pre-filled syringes. The company has built a proprietary technology stack around advanced organic chemistry, novel purification processes, ready-to-use sterile formulations, and a "Smart Dyes" platform targeting fluorescence-guided surgery, supported by 14 patent families encompassing 222 patents and 38 marketing authorizations plus 3 CE marks across multiple geographies.

The company's revenue model is predominantly B2B pharmaceutical product sales to hospital pharmacies, surgical teams, and group purchasing organizations, supplemented by licensing and distribution arrangements with international partners covering more than 25 countries. Go-to-market is hybrid: direct distribution via Key Account Managers and Medical Science Liaison teams in France since 2020 and in the United Kingdom since November 2023, and indirect distribution through Sagent Pharmaceuticals in the United States and a network of 20+ international distributors across Europe, the Middle East, Asia-Pacific, and Latin America. Approximately 20% of revenue is reinvested into R&D, and the company is pursuing a strategic refocusing on fluorescence-guided surgery with targeted divestments of non-core legacy pharmaceutical assets such as Fegenor and Quitaxon. The company is B Corp-certified (November 2023) and has raised €120 million in debt financing (September 2021) to fund international expansion, lab capacity, and the acquisition of Apollo Pharmaceuticals USA.

Name

Provepharm life Solutions

Legal name

PROVEPHARM LIFE SOLUTIONS SA

Website

https://www.provepharm.com/

Company type

Private

Founded year

1998

Operating status

Operating

Headcount range

101–250 employees

Short description

Provepharm Life Solutions is a French specialty pharmaceutical company developing and commercializing high-purity medical dyes—primarily methylene blue and indigo carmine formulations—for surgical visualization, endoscopic procedures, and fluorescence-guided surgery, sold to hospitals in over 25 countries.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceutical Medical Dyes

NAICS

Pharmaceutical Preparation Manufacturing (325412), In-Vitro Diagnostic Substance Manufacturing (325413), Pharmaceutical and Medicine Manufacturing (32541)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

akta.pro secondary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

Keywords

• Medical dyes
• Surgical visualization
• Fluorescence-guided surgery
• Diagnostic dyes
• Specialty pharmaceuticals

Headquarters

HQ city

Marseille

HQ country

France

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Medical Dyes Product Sales: Sale of proprietary medical dyes including methylene blue (ProvayBlue, Proveblue), indigo carmine (Provingo, PROVENDO, Bludigo, Blumyne), and surgical dyes (PROVEDYE). Products sold as pharmaceuticals (medicines) and medical devices directly and via distribution partners.
2. Pharmaceutical Portfolio: Additional pharmaceutical products including antidotes, vitamins (A, E), and specialty medications (Fegenor, Quitaxon) sold in France.
3. International Distribution Licensing: Distribution licenses granted to international partners in over 25 countries, generating revenue through product supply and licensing arrangements.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Core offering

Provepharm develops, manufactures, and commercializes proprietary medical dyes—primarily methylene blue and indigo carmine formulations—for surgical visualization, endoscopic procedures, ureteral detection during abdomino-pelvic surgery, and treatment of methemoglobinemia. The portfolio also includes specialty pharmaceuticals (Fegenor fenofibrate, Quitaxon doxepin) and vitamin supplements, all marketed as ready-to-use, hospital-grade formulations under ISO 13485 and GMP quality systems.

Product overview

Provepharm Life Solutions is a pharmaceutical company specializing in medical dyes and hospital-grade medications. The core portfolio centers on surgical and diagnostic dyes including methylene blue (Proveblue/PROVEDYE), indigo carmine (Provingo/Blumyne/PROVENDO/Bludigo), and methylthioninium chloride products used for visualization in surgical procedures. Additional therapeutic products include antidotes for methemoglobinemia, lipid-modifying agents (Fegenor), dermatological treatments (Quitaxon), and vitamin supplements (Vitamine A/E). The company operates through direct distribution in France and UK markets, with international expansion via partnerships including Sagent Pharmaceuticals in the US. Products are marketed as ready-to-use formulations in various presentations (ampoules, vials, pre-filled syringes) under strict pharmaceutical quality standards.

Differentiator

Problem solved

Functional benefit

Brands

• ProvayBlue: Methylene blue injection for acquired methemoglobinemia treatment
• Bludigo
• Blumyne
• PROVEDYE
• PROVENDO
• Proveblue
• Provingo
• Quitaxon
• Fegenor

Products and services

• ProvayBlue (Methylene Blue Injection USP) Methylene blue injection medication indicated for treatment of acquired methemoglobinemia, distributed in single-dose vials for hospital and clinical use.
• Proveblue (Methylthioninium Chloride Proveblue) Methylthioninium chloride injection solution used as an antidote for methemoglobinemia treatment; EMA-approved medicinal product with comprehensive clinical documentation.
• Provingo (Indigo Carmine Injection) Indigo carmine (indigotine) injection solution for surgical visualization; indicated for ureteral visualization and detection during abdominal and pelvic surgery procedures.
• Blumyne (Indigotine Surgical Dye) Indigotine injection solution for intraoperative visualization; UK-approved surgical dye indicated for ureteral identification and prevention of iatrogenic injury during surgical procedures.
• Bludigo (Indigotindisulfonate Sodium Injection) FDA-approved indigotindisulfonate sodium injection marketed by Sagent Pharmaceuticals under partnership with Provepharm; diagnostic agent for urological and surgical applications.
• PROVEDYE (Methylene Blue Solution) Methylene blue pharmaceutical solution available in ampoules and vials; used for tissue staining, diagnostic visualization, and methemoglobinemia treatment across hospital and surgical settings.
• PROVENDO (Indigo Carmine Solution) Indigo carmine injection solution for endoscopic and surgical applications; available in ampoule format for direct hospital and clinical use.
• Fegenor (Fenofibrate) Lipid-modifying agent containing fenofibrate for treatment of hyperlipidemia and dyslipidemia; part of cardiovascular product portfolio.
• Quitaxon (Doxepin) Doxepin hydrochloride medication available in film-coated tablet form; tricyclic antidepressant for treatment of depression and anxiety disorders.
• Vitamine A Provepharm Retinol palmitate injection solution for vitamin A supplementation; used for treatment of vitamin A deficiency and as adjunctive therapy in various clinical conditions.
• Vitamine E Provepharm Alpha-tocopherol acetate injection solution providing vitamin E supplementation; antioxidant therapy for clinical nutritional support applications.

Quantifiable outcome

• 1.3 million units sold worldwide
• +3 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• Sagent PharmaceuticalscoreChannel Partner/ Reseller/ Distributor · 3 December 2025Strategic commercial partnership for US market distribution of diagnostic dyes. Sagent Pharmaceuticals, a major player in injectable and generic medications, will distribute Bludigo (indigo carmine injection) and two new diagnostic dyes launching in 2026. This partnership leverages Sagent's market expertise and commercial infrastructure to accelerate market access in the $200M+ US diagnostic dye segment.
• Apollo PharmaceuticalscoreOthersUS-based distributor of injectable products acquired by Provepharm using part of the €120M funding. Apollo reported 30% growth with revenue of €48.5M and EBITDA of €32M prior to acquisition.

Scale indicators13 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• Akorn Operating Company: US specialty pharmaceutical company with historic strength in hospital injectable products including methylene blue formulations. Direct competitor in injectable dye products for hospital use, particularly in the US market.
• Bracco Imaging: Global leader in diagnostic imaging agents, including injectable contrast media used in surgical and endoscopic visualization. Comparable in product category (imaging/diagnostic injectables), customer base (hospital radiology/surgical teams), and regulatory pathway.
• Guerbet: French-headquartered specialist in medical imaging contrast media and related pharmaceutical solutions. Directly comparable to Provepharm in the surgical and diagnostic visualization category, with similar focus on injectable hospital-administered dyes and a French/European operational base.
• Dr. Franz Köhler Chemie: German specialty pharmaceutical manufacturer focused on medical dyes and contrast agents (including methylene blue and indigo carmine products). Direct competitor in the European surgical/diagnostic dye niche with overlapping product categories and hospital customer base.
• Lantheus Holdings: US specialty pharmaceutical company focused on diagnostic imaging agents, including injectables used in clinical visualization. Direct comparable in business model, regulatory positioning, and focus on differentiated hospital-administered diagnostic products.

Broad incumbents

• GE HealthCare: Global medical imaging and diagnostics giant offering contrast media, imaging equipment, and visualization solutions. Overlaps with Provepharm's surgical visualization mission at a much broader scale and via integrated equipment-plus-consumables model.
• Hikma Pharmaceuticals: Major generic injectable pharmaceutical manufacturer with global hospital-focused distribution. Comparable as a competitor in injectable dye products and broader hospital injectables, with significantly larger scale and broader portfolio.
• Mallinckrodt Pharmaceuticals: Large specialty pharmaceutical company with a portfolio of injectable hospital products including dyes and contrast agents. Comparable in product category and customer base, though operates at much greater scale and across many therapeutic areas beyond dyes.

Emerging players

• Recipharm: European pharmaceutical CDMO and specialty injectable manufacturer with capabilities in sterile injectable fill-finish relevant to dye formulations. Partial overlap as a potential manufacturing partner or competitor in injectable specialty products for hospital channels.

Others

• Sagent Pharmaceuticals: US specialty injectable pharmaceutical company and Provepharm's US distribution partner for Bludigo and upcoming diagnostic dyes. While not a direct competitor (currently a partner), operates in the same injectable specialty hospital channel and represents a potential comparability benchmark for US commercial scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@provepharmlifesolutions8171
• LinkedInlinkedin.com/company/provepharmlifesolutions
• Xx.com/provepharm

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries2 records

Funding overview

Funding rounds3 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Provepharm life Solutions